Search | Clinical Trials Finder

Conditions: X-Linked Hypophosphatemia
Interventions: Burosumab; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 1 Year to 4 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: New Haven, Connecticut • Indianapolis, Indiana • St Louis, Missouri

Conditions: Nephrolithiasis, Urolithiasis, Idiopathic Hypercalciuria, Vitamin D Deficiency, Disorder of Vitamin D
Interventions: Ergocalciferol; Drug
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Arterial Dysfunction, Chronic Kidney Disease
Interventions: Cholecalciferol, Calcitriol; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria, Renal Tubular Toxicity
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Iron-deficiency, Pregnancy Anemia, Obesity
Interventions: Jarrow Formulas Oral Bovine Lactoferrin Supplement; Dietary Supplement
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Polycystic Ovary Syndrome, Vitamin D Deficiency
Interventions: Vitamin D3; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 16 Years to 48 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions: CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules; Drug · Other
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: X-linked Hypophosphatemia
Interventions: burosumab; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: San Francisco, California • New Haven, Connecticut • Indianapolis, Indiana + 2 more

Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Interventions: Telemedicine, Face-to-Face; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Henderson, North Carolina • Laurinburg, North Carolina • Lumberton, North Carolina + 1 more

Conditions: Pregnancy, Autistic Disorder, Folic Acid Deficiency
Interventions: Prenatal supplement; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Urinary Incontinence, Vitamin D Deficiency
Interventions: Vitamin D3 50,000 IU, Placebo; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years and older · Female only
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lynch Syndrome, Lynch Syndrome I, Lynch Syndrome II, Lynch Syndrome I (Site-specific Colonic Cancer), HNPCC, HNPCC Gene Mutation, Hereditary Cancer Syndrome, Hereditary Cancer, MLH1 Gene Mutation, MLH1 Gene Deletion+Duplication, MLH1 Loss of Expression, MLH1 Gene Inactivation, MSH2 Gene Mutation, MSH2 Gene Deletion+Duplication, MSH2 Loss of Expression, MSH2 Gene Inactivation, MSH6 Gene Mutation, MSH6 Loss of Expression, MSH6 Gene Inactivation, PMS2 Gene Mutation, PMS2 Gene Inactivation, PMS2 Loss of Expression
Interventions: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System); Diagnostic Test
Lead sponsor: San Raffaele University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Timeline: 2023 – 2034
U.S. locations: 1
States / cities: Monrovia, California

Conditions: End Stage Renal Disease
Interventions: GHRP-1/AG 70 mg depot in ESRD, Placebo; Drug · Other
Lead sponsor: QLT Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: New Orleans, Louisiana • Rochester, Minnesota

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Paricalcitol, Ergocalciferol; Drug
Lead sponsor: Salem Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Salem, Virginia

Conditions: Hyperphosphatemia, Anemia, Iron Deficiency, Renal Insufficiency
Interventions: Ferric Citrate 1 gram Oral Tablet, Standard of care phosphate-lowering therapy; Drug
Lead sponsor: USRC Kidney Research; Network
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Anchorage, Alaska • Mesa, Arizona • Pine Bluff, Arkansas + 6 more

Conditions: Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
Interventions: DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF; Drug · Combination Product
Lead sponsor: Prism Health North Texas; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Vitamin D Deficiency, Pregnancy
Interventions: cholecalciferol (vitamin D3), cholecalciferol; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 564 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions: Iron isomaltoside/ferric derisomaltose, Iron sucrose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 141
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more

Conditions: Very Low Birth Weight Infant, Premature Infants, Anemia of Prematurity, Iron Deficiency, Anaemia in Children, Extremely Low Birth Weight
Interventions: 6 mg/kg of oral iron as ferrous sulfate administered every other day., 6 mg/kg of oral iron as ferrous sulfate administered every day.; Dietary Supplement
Lead sponsor: CHRISTUS Health; Other
Eligibility: 26 Weeks to 32 Weeks
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pregnancy Related, Anemia, Iron Deficiency, Anemia of Pregnancy
Interventions: Ferumoxytol, Ferrous Sulfate; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Infertility, Vitamin D Deficiency
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions: FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate); Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Epithelial Ovarian Cancer, Anemia, Iron Deficiency Anemia
Interventions: Iron Sucrose; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: End Stage Renal Disease
Interventions: Etanercept, Placebo; Drug
Lead sponsor: Kaysen, George A., M.D., Ph.D.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

Vitamin D Repletion in Stone Formers With Hypercalciuria

Vitamin D and Arterial Function in Patients With Chronic Kidney Disease

Evaluation of Albuminuria HIV-Infected Patients

Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy

Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

Telemedicine vs. Face-to-Face Cancer Genetic Counseling

Screening for Metabolic Problems in Mothers of Children With Autism and Typically Developing Children

Vitamin D Supplementation in Older Adults With Urinary Incontinence

Lynch Syndrome X-Talk of Enteral Mucosa With Immune System

A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients

Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants

Doravirine and Weight Gain in Antiretroviral Naive

Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Pilot Trial Investigating Every Other Day Dosing of Oral Iron in Premature Infants (IQONic)

Early Antenatal Support for Iron Deficiency Anemia

Effect of Vitamin D Supplementation on In-vitro Fertilization (IVF) Outcomes

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients